Cubist Systematic Strategies, LLC Adagio Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	N/A	53,499 Added 66.09%	134,452 $445,000
Q1 2024 May 15, 2024	BUY	N/A	55,215 Added 214.53%	80,953 $267,000
Q4 2023 Feb 14, 2024	BUY	N/A	17,875 Added 227.33%	25,738 $85,000
Q3 2023 Nov 14, 2023	SELL	N/A	-21,948 Reduced 73.62%	7,863 $26,000
Q2 2023 Aug 14, 2023	BUY	N/A	29,811 New	29,811 $98,000
Q4 2022 Feb 14, 2023	BUY	$3.08 - $4.05 $11,032 - $14,507	3,582 New	3,582 $11,000
Q2 2022 Aug 15, 2022	SELL	$2.54 - $4.52 $18,034 - $32,091	-7,100 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.81 - $10.77 $27,051 - $76,467	7,100 New	7,100 $32,000

63.9M

2.3K

2.1K

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.